CN113603570B - Leonurine borneol derivative, preparation method and application thereof - Google Patents

Leonurine borneol derivative, preparation method and application thereof Download PDF

Info

Publication number
CN113603570B
CN113603570B CN202111139180.8A CN202111139180A CN113603570B CN 113603570 B CN113603570 B CN 113603570B CN 202111139180 A CN202111139180 A CN 202111139180A CN 113603570 B CN113603570 B CN 113603570B
Authority
CN
China
Prior art keywords
dichloromethane
volume ratio
mass
preparation
room temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111139180.8A
Other languages
Chinese (zh)
Other versions
CN113603570A (en
Inventor
李峰
宋艳
宋晓峰
李文保
刘晓坤
张姗姗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Weifang University of Science and Technology
Original Assignee
Weifang University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Weifang University of Science and Technology filed Critical Weifang University of Science and Technology
Priority to CN202111139180.8A priority Critical patent/CN113603570B/en
Publication of CN113603570A publication Critical patent/CN113603570A/en
Application granted granted Critical
Publication of CN113603570B publication Critical patent/CN113603570B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/05—Preparation of ethers by addition of compounds to unsaturated compounds
    • C07C41/06—Preparation of ethers by addition of compounds to unsaturated compounds by addition of organic compounds only
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/367—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C07C65/26—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides an leonurine borneol derivative, which is a compound shown as B1 or B2 or a stereoisomer thereof or a pharmaceutically acceptable salt form thereof, and also provides a preparation method of the derivative and application of the derivative in medicines for preventing and treating nervous system diseases or cardiovascular and cerebrovascular diseases. The leonurine borneol derivative provided by the invention has a remarkable neuroprotective effect, can repair nerve cell injury, and also has a remarkable lipid-lowering function, so that the leonurine borneol derivative has a remarkable pharmacological activity for treating and preventing nervous system and cardiovascular and cerebrovascular diseases, and has an important significance for developing novel medicaments for preventing or treating the nervous system and the cardiovascular and cerebrovascular diseases.

Description

Leonurine borneol derivative, preparation method and application thereof
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to an leonurine borneol derivative, a preparation method thereof and application thereof in medicines for preventing and treating nervous system diseases or cardiovascular and cerebrovascular diseases.
Background
Stroke is a major disease seriously harming human health and life safety in the world at present, and has the characteristics of high morbidity, high disability rate and high mortality; stroke is a group of diseases in which brain tissue is damaged due to sudden rupture of cerebral blood vessels or the inability of blood to flow into the brain due to vascular occlusion, and includes ischemic and hemorrhagic strokes. The incidence rate of ischemic stroke is higher than hemorrhagic stroke, and accounts for 60-70% of the total stroke. In the world, more than one thousand new strokes occur every year, and investigation shows that urban and rural combined stroke becomes the first cause of death in China and is also the leading cause of disability of adults in China, so that serious burden is brought to the society and families, and effective stroke prevention and treatment measures are urgently needed. There are different treatment modes for stroke according to the occurrence part, wherein the drug therapy is one of the main treatment modes adopted at present, including thrombolysis, antiplatelet therapy, early anticoagulation, neuroprotection and the like. Although great progress has been made in the research of drugs for treating stroke, many problems remain unsolved: such as strict time window requirements of thrombolytic therapy, drug selection and combined use of anti-coagulation and defibrination therapy, clinical effectiveness and safety of neuroprotective drugs, and the like. Therefore, a safe and effective medicament with a wider treatment window is urgently needed for treating the cerebral apoplexy clinically.
Leonurine is firstly separated from motherwort in 1930, has the functions of promoting blood circulation to disperse blood clots, inducing diuresis to alleviate edema, exciting uterus, enhancing myocardial contractility, exciting respiration, protecting cardiac blood vessels, protecting central nervous system, etc., and may have the functions of resisting oxidation, resisting apoptosis, regulating mitochondrial function, resisting inflammation, etc.
The borneol is crystal extracted from resin and volatile oil processed product of borneol spice plant borneol tree, and the borneol is pungent and bitter in taste and slightly cold in nature; heart meridian entered; the product has effects of inducing resuscitation, refreshing mind, clearing heat, removing toxic substance, improving eyesight, and removing nebula, and can be used for treating fever, hyperpyrexia, coma, apoplexy, phlegm syncope, convulsion, summer-heat dampness covering resuscitation, pharyngitis, deafness, aphtha, swelling of teeth, skin ulcer, carbuncle, malnutritional hemorrhoid, conjunctival congestion, swelling and pain, nebula, and eye covering.
No beneficial matrine borneol derivative is reported in the prior art.
Disclosure of Invention
Aiming at the problems in the prior art, the invention provides an leonurine borneol derivative, a preparation method and application thereof in medicines for preventing and treating nervous system diseases or cardiovascular and cerebrovascular diseases, and the following aims are achieved:
the leonurine borneol derivative has a nerve protection effect and can repair nerve cell damage; has effects of reducing cerebral infarction area and decreasing neurobehavioral score.
In order to solve the technical problems, the invention adopts the following technical scheme:
an leonurine borneol derivative, which is a compound shown as B1 or B2 or a stereoisomer thereof or a pharmaceutically acceptable salt form thereof:
Figure 100837DEST_PATH_IMAGE001
the following is a further improvement of the above technical solution:
the preparation method of the B1 comprises the following steps:
(1) preparation of M-1
Adding camphene, 2-bromoethanol and montmorillonite K-10 into dichloromethane, and stirring at room temperature for 24 hours to obtain M-1;
the molar ratio of camphene to 2-bromoethanol is 1: 1.1; the mass ratio of the camphene to the montmorillonite K-10 is 1: 2; the mass-volume ratio of camphene to dichloromethane is 1g:13.3 mL;
(2) preparation of M-2
Dissolving syringic acid in dichloromethane to obtain dichloromethane solution of syringic acid, sequentially adding potassium hydroxide, potassium carbonate, tetrabutylammonium bromide and water, slowly dropwise adding the dichloromethane solution containing M-1 under stirring, completing dropwise addition for 30 minutes, and reacting at room temperature for 24 hours to obtain M-2;
the molar ratio of the syringic acid to the potassium hydroxide to the potassium carbonate to the tetrabutylammonium bromide to the M-1 is 10:18:10:1: 10;
the mass volume ratio of the tetrabutylammonium bromide to the water is 1g:30 mL;
in the dichloromethane solution of the syringic acid, the mass-volume ratio of the syringic acid to the dichloromethane is 1g:5 mL;
the mass-volume ratio of M-1 to dichloromethane of the dichloromethane solution containing M-1 is 1g:1.28 mL;
(3) preparation of M-4
Dissolving M-2 in DCM at room temperature, sequentially adding M-3, 4-dimethylaminopyridine p-toluenesulfonate and N, N' -diisopropylcarbodiimide, and reacting for 5 hours to obtain M-4;
the molar ratio of the M-2, the M-3, the 4-dimethylaminopyridine p-toluenesulfonate to the N, N' -diisopropylcarbodiimide is 1:1.5:2: 2;
the mass-to-volume ratio of M-2 to DCM is 1g: 15.9 mL;
(4) to obtain B1
Dissolving M-4 in dichloromethane, dripping trifluoroacetic acid at 0 ℃, stirring for 5 min, heating to room temperature, and reacting for 8 h to obtain B1;
the mass-volume ratio of the M-4 to the dichloromethane is 1 mg: 0.05 mL; the volume ratio of the dichloromethane to the trifluoroacetic acid is 20: 1;
the preparation method of the B2 comprises the following steps:
(1) preparation of M-5
Dissolving syringic acid in dichloromethane to obtain a dichloromethane solution of syringic acid, sequentially adding potassium hydroxide, potassium carbonate, tetrabutylammonium bromide and water, slowly dropwise adding a dichloromethane solution of bromoborneol under stirring, completing dropwise addition within 30 minutes, and reacting at room temperature for 24 hours to obtain M-5;
the molar ratio of the syringic acid to the potassium hydroxide to the potassium carbonate to the tetrabutylammonium bromide to the bromoborneol is 10:18:10:1: 10;
the mass volume ratio of the tetrabutylammonium bromide to the water is 1g:30 mL;
in the dichloromethane solution of the syringic acid, the mass-volume ratio of the syringic acid to the dichloromethane is 1g:5 mL;
in the dichloromethane solution of the bromoborneol, the mass volume ratio of the bromoborneol to the dichloromethane is 1g: 1.54 mL;
(2) preparation of M-6
Dissolving M-5 in DCM at room temperature, sequentially adding M-3, 4-dimethylaminopyridine p-toluenesulfonate and N, N' -diisopropylcarbodiimide, and reacting at room temperature for 5 h to obtain M-6;
the molar ratio of the M-5, the M-3, the 4-dimethylaminopyridine p-toluenesulfonate to the N, N' -diisopropylcarbodiimide is 1:1.5:2: 2;
the mass-to-volume ratio of the M-5 to the DCM is 1g:18.2 mL;
(3) preparation B2
Dissolving M-6 in dichloromethane, dripping trifluoroacetic acid at 0 ℃, stirring for 5 min, heating to room temperature, and reacting for 8 h to obtain B2;
the mass-volume ratio of the M-6 to the dichloromethane is 1 mg: 0.05 mL; the volume ratio of the dichloromethane to the trifluoroacetic acid is 20: 1.
The structural formulas of M-1, M-2, M-3, M-4, M-5 and M-6 are as follows:
Figure 516775DEST_PATH_IMAGE003
。
the pharmaceutically acceptable salts of the leonurine borneol derivatives comprise inorganic acid and organic acid derived salts; inorganic and organic acids include hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, trifluoromethanesulfonic, benzenesulfonic, p-toluenesulfonic, 1-naphthalenesulfonic, 2-naphthalenesulfonic, acetic, trifluoroacetic, malic, tartaric, citric, lactic, oxalic, succinic, fumaric, maleic, benzoic, salicylic, phenylacetic and mandelic acids.
The invention also provides the application of the leonurine borneol derivative in medicaments for preventing and treating nervous system diseases or cardiovascular and cerebrovascular diseases.
The nervous system diseases include apoplexy, Alzheimer disease, Parkinson disease, cerebral palsy, brain atrophy, hypomnesis, insomnia, amnesia, neurasthenia, epilepsy, schizophrenia, confusion, and attention deficit disorder; the cardiovascular and cerebrovascular diseases comprise hyperlipidemia, hypertension, hyperglycemia, atherosclerosis, cerebral arteriosclerosis, transient ischemic attack, and multiple sclerosis.
Compared with the prior art, the invention has the beneficial effects that:
pharmacological experiments prove that the derivative based on the leonurine borneol structure has the nerve protection effect, can repair nerve cell injury, and also has the function of obviously reducing blood fat, so that the derivative has the pharmacological activity of remarkably treating and preventing nervous system and cardiovascular and cerebrovascular diseases.
In a PC12 nerve cell injury model caused by oxygen sugar deprivation, compared with a leonurine group, the compounds B1 and B2 can obviously improve the survival rate of nerve cells, and have the same effect as a positive medicine Baicalein;
the compounds B1 and B2 can effectively reduce the cerebral infarction area and improve the neurobehavioral effect, and the effect of the compounds B1 and B2 at the concentration of 20 mg/kg is better than that of the positive drug group edaravone.
Drawings
FIG. 1 is a bar graph of the cerebral infarction area of the derivatives B1 and B2 caused by transient cerebral ischemia of rats;
FIG. 2 is a neuro-behavioral score of derivatives B1, B2 after transient cerebral ischemia in rats;
FIG. 3 is a graph showing the improvement of transient cerebral ischemia in rats by derivatives B1 and B2.
Detailed Description
The following embodiments better illustrate the present invention, but the present invention is not limited to the following examples.
Example 1: the synthetic route of M-1 is as follows:
adding camphene (15.0g, 0.1mol), 2-bromoethanol (13.6g, 0.11mol) and montmorillonite K-10 (30.0 g) into dichloromethane (200 mL), stirring at room temperature for 24 hours, filtering after the reaction is completed, washing a filter cake with saturated saline (100 mL), drying with anhydrous sodium sulfate, concentrating under reduced pressure, and performing column chromatography to obtain colorless oil M1 with the yield of 72%; ESI-MS: (M/z,%) =260[ M + H]+。
Example 2: the synthetic route of M-2 is as follows:
dissolving syringic acid (5.94 g, 30 mmol) in dichloromethane (30 mL) to obtain a dichloromethane solution of syringic acid, sequentially adding potassium hydroxide (3.0 g, 54 mmol), potassium carbonate (4.1 g, 30 mmol), tetrabutylammonium bromide (1.0 g,3 mmol) and water (30 mL), slowly dropwise adding a dichloromethane (10 mL) solution containing M-1 (7.8 g, 30 mmol) while stirring, dropping for 30 minutes, reacting at room temperature for 24 hours, adjusting pH = 5 after the reaction is completed, separating an organic layer, washing an organic phase with water, using 30mL of water, washing with water, concentrating to dryness, and performing column chromatography to obtain M-2 with the yield of 51%.1H NMR (500 MHz, DMSO-d 6) δ = 7.28 (s, 2H), 4.13 (t, 2H), 3.81 (s, 6H), 3.76 (t, 2H), 3.04 (m, 1H), 1.86-1.55 (m, 7H), 1.01 (s, 3H), 0.97 (s, 6H). ESI-MS：（m/z，%）= 379 [M+H]+。
Example 3: the synthetic route of M-4 is as follows:
dissolving M-2 (6.3 g, 16.66 mmol) in 100mL DCM at room temperature, sequentially adding M-3 (6 g, 24.98 mmol), 4-dimethylaminopyridine p-toluenesulfonate (9.8 g, 33.32 mmol) and N, N' -diisopropylcarbodiimide (4.2 g, 33.32 mmol), reacting for 5 h, washing with water, extracting with DCM, collecting the lower solution, evaporating to dryness, and performing column chromatography to obtain white foamy solid M-4 with yield of 67%.
1H NMR (500 MHz, DMSO-d 6) δ = 9.31 (s, 1H), 8.33 (s, 1H), 7.20 (s, 2H), 4.24-4.20 (m, 1H), 4.13 (t, 2H), 4.02 (q, 1H), 3.80 (s, 6H), 3.75 (t, 2H), 3.04 (m, 1H), 1.98-1.56 (m, 13H), 1.46 (s, 9H), 1.37 (s, 9H), 1.01 (s, 3H), 0.97 (s, 6H). ESI-MS：（m/z，%）= 692 [M+H]+。
Example 4: the synthetic route of B1 is as follows:
dissolving M-4 (200 mg, 0.29 mmol) in 10mL dichloromethane, dripping 0.5 mL trifluoroacetic acid at 0 ℃, stirring for 5 min, raising the temperature to room temperature for reacting for 8 h, evaporating the solvent to remove the trifluoroacetic acid after the reaction is finished, adding 20 mL water, extracting an aqueous phase with dichloromethane (10 mL x 3), and evaporating the aqueous phase to dryness to obtain a solid B1 with the yield of 92%.
1H NMR (500 MHz, CD3OD) δ = 7.36 (s, 2H), 5.36 (dd, 1H), 4.39 (t, 2H), 3.91 (s, 6H), 4.13 (t, 2H), 3.79 (t, 2H), 3.66-3.54 (m, 4H), 3.04 (m, 1H), 1.89-1.57 (m, 11H), 1.00 (s, 3H), 0.97 (s, 6H). ESI-MS：（m/z，%）= 492 [M+H]+。
Example 5: the synthetic route of M-5 is as follows:
dissolving syringic acid (5.94 g, 30 mmol) in dichloromethane (30 mL) to obtain a dichloromethane solution of syringic acid, sequentially adding potassium hydroxide (3.0 g, 54 mmol), potassium carbonate (4.1 g, 30 mmol), tetrabutylammonium bromide (1.0 g,3 mmol) and water (30 mL), slowly dropwise adding a dichloromethane (10 mL) solution of bromoborneol (6.5 g, 30 mmol) while stirring, completing the dropwise addition within 30 minutes, reacting at room temperature for 24 hours, adjusting the pH after the reaction is completed to = 5, separating an organic layer, washing an organic phase with water, wherein the amount of water is 30mL, concentrating to be dry after washing, and performing column chromatography to obtain M-5, wherein the yield is 46%.
1H NMR (500 MHz, DMSO-d 6) δ = 7.29 (s, 2H), 3.80 (s, 6H), 3.34 (m, 1H), 2.06-1.85 (m, 2H), 1.66-1.45 (m, 5H), 0.91 (s, 3H), 0.87 (s, 6H). ESI-MS：（m/z，%）= 335 [M+H]+。
Example 6: the synthetic route of M-6 is as follows:
dissolving M-5 (5.5 g, 16.66 mmol) in 100mL DCM at room temperature, adding M-3 (6 g, 24.98 mmol), 4-dimethylaminopyridine p-toluenesulfonate (9.8 g, 33.32 mmol) and N, N' -diisopropylcarbodiimide (4.2 g, 33.32 mmol) in sequence, reacting for 5 h at room temperature, washing with water, extracting with DCM, collecting the lower solution, evaporating to dryness, and performing column chromatography to obtain a white foamy solid M-6 with the yield of 61%.1H NMR (500 MHz, DMSO-d 6) δ = 9.30 (s, 1H), 8.36 (s, 1H), 7.15 (s, 2H), 4.26-4.21 (m, 1H), 4.02 (q, 1H), 3.80 (s, 6H), 3.34 (m, 1H), 2.06-1.85 (m, 2H), 1.68-1.51 (m, 9H), 1.46 (s, 9H), 1.43 (s, 9H), 0.92 (s, 3H), 0.87 (s, 6H). ESI-MS：（m/z，%）= 648 [M+H]+。
Example 7: the synthetic route of B2 is as follows:
dissolving M-6 (200 mg, 0.31 mmol) in 10mL dichloromethane, dropping 0.5 mL trifluoroacetic acid at 0 ℃, stirring for 5 min, raising the temperature to room temperature for reaction for 8 h, evaporating the solvent after the reaction to remove the trifluoroacetic acid, adding 20 mL water, extracting the aqueous phase with dichloromethane (10 mL x 3), evaporating the aqueous phase to dryness to obtain solid B2, wherein the yield is 95%.
1H NMR (500 MHz, CD3OD) δ = 7.46 (s, 2H), 5.38 (dd, 1H), 3.83 (s, 6H), 4.23 (t, 2H), 3.65-3.54 (m, 4H), 3.35 (m, 1H), 2.05-1.87 (m, 2H), 1.67-1.51 (m, 9H), 0.90 (s, 3H), 0.87 (s, 6H). ESI-MS：（m/z，%）= 448 [M+H]+。
Example 8: determination of the Effect of Boragine derivatives on the model of PC12 nerve cell injury caused by oxygen deprivation (OGD)
Ischemic stroke is a clinical syndrome of focal nervous system symptoms and signs caused by the disorder of oxygen supply and energy metabolism of brain tissues due to the stenosis or blockage of cerebral vessels. The PC12 cell is rat pheochromocytoma cell, has the characteristics of a plurality of nerve cells, is often used for research instead of the nerve cells, and is widely used for research of in vitro ischemic injury. The Oxygen-glucose depletion (OGD) model can better simulate the damage of cerebral ischemia to nerve cells, and provides a simple and easy in-vitro model for researching the neuroprotective effect of a medicament.
Grouping experiments: a blank control group, a model group, a positive drug group (Baicalein) 10 mu mol, 3 dosage groups (10, 20 and 40 mu mol) of leonurine and 3 dosage groups (10, 20 and 40 mu mol) of test compounds;
sample treatment: dissolving the sample by DMSO, and storing at low temperature;
when the drugs of the different dosage groups are added into a 96-well plate, the drugs need to be diluted 1000 times to obtain a diluent containing the drugs to be screened.
Materials: DMEM sugar free medium, high glucose DMEM medium containing 10% FBS was purchased from Gibco; PC12 nerve cells were purchased from biochemical cells in shanghai, a chinese academy of sciences.
The experimental method comprises the following steps: collecting recovered PC12 cells at 2 × 104Adding each cell/well into 96-well plate, adding 50 μ L of high-sugar DEME culture medium containing 10% FBS into each well, incubating overnight, replacing with new high-sugar DEME culture medium containing 10% FBS, adding 20 μ L of diluent containing drug to be screened, reacting for 24 hr, replacing with 50 μ L of sugar-free DEME culture medium, placing in anoxic incubator (5% CO)2，1%O2) Medium 2h, then replaced with 50. mu.L of high sugar DEME medium containing 10% FBS, while adding 20. mu.L of diluent containing the drug to be screened, and placed in a common cell incubator (95% O)2，5% CO2) Cell viability was measured 24h later using MTT (final concentration should be 0.5mg/ml when added to 96-well plates). The results of the experiment are shown in table 1.
TABLE 1 detection results of the survival rate of nerve cells
Figure 758311DEST_PATH_IMAGE004
As can be seen from table 1: in the model of oxygen sugar deprivation induced PC12 nerve cell injury, the compounds B1 and B2 have significant difference compared with the OGD injury group, which indicates that the compound has a certain neuroprotective effect.
Example 9: determination of drug effect evaluation of leonurine borneol derivative on rat middle artery occlusion model
Grouping experiments: model group, positive drug group (A) edaravone (20 mg/kg), B1 (20 mg/kg), B2 (20 mg/kg) 8 rats per group.
The experimental method comprises the following steps: SD male rats weighing 250-. 2, 3, 5-triphenyltetrazolium chloride (TTC) staining to determine cerebral infarction area; longa test tests neurobehavioral scores.
The experimental results are as follows: dead rats and failed molding rats were removed after 24h, and the number of rats for statistics was 8 per group.
TABLE 2 cerebral infarct size and neuroethological scores
Figure 488369DEST_PATH_IMAGE005
The results show that: the compounds B1 and B2 have the effect of improving the cerebral infarction area and neurobehavioral at the concentration of 20 mg/kg.
The above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions.

Claims (2)

1. An leonurine borneol derivative is characterized in that: the leonurine borneol derivative is a compound shown as B1 or B2 or a pharmaceutically acceptable salt form thereof:
Figure 779003DEST_PATH_IMAGE001
；
the preparation method of the B1 comprises the following steps:
(1) preparation of M-1
Adding camphene, 2-bromoethanol and montmorillonite K-10 into dichloromethane, and stirring at room temperature for 24 hours to obtain M-1;
the molar ratio of camphene to 2-bromoethanol is 1: 1.1; the mass ratio of the camphene to the montmorillonite K-10 is 1: 2; the mass-volume ratio of camphene to dichloromethane is 1g:13.3 mL;
(2) preparation of M-2
Dissolving syringic acid in dichloromethane to obtain dichloromethane solution of syringic acid, sequentially adding potassium hydroxide, potassium carbonate, tetrabutylammonium bromide and water, slowly dropwise adding the dichloromethane solution containing M-1 under stirring, completing dropwise addition for 30 minutes, and reacting at room temperature for 24 hours to obtain M-2;
the molar ratio of the syringic acid to the potassium hydroxide to the potassium carbonate to the tetrabutylammonium bromide to the M-1 is 10:18:10:1: 10;
the mass volume ratio of the tetrabutylammonium bromide to the water is 1g:30 mL;
in the dichloromethane solution of the syringic acid, the mass-volume ratio of the syringic acid to the dichloromethane is 1g:5 mL;
the mass-volume ratio of M-1 to dichloromethane of the dichloromethane solution containing M-1 is 1g:1.28 mL;
(3) preparation of M-4
Dissolving M-2 in DCM at room temperature, sequentially adding M-3, 4-dimethylaminopyridine p-toluenesulfonate and N, N' -diisopropylcarbodiimide, and reacting for 5 hours to obtain M-4;
the molar ratio of the M-2, the M-3, the 4-dimethylaminopyridine p-toluenesulfonate to the N, N' -diisopropylcarbodiimide is 1:1.5:2: 2;
the mass-to-volume ratio of M-2 to DCM is 1g: 15.9 mL;
(4) to obtain B1
Dissolving M-4 in dichloromethane, dripping trifluoroacetic acid at 0 ℃, stirring for 5 min, heating to room temperature, and reacting for 8 h to obtain B1;
the mass-volume ratio of the M-4 to the dichloromethane is 1 mg: 0.05 mL; the volume ratio of the dichloromethane to the trifluoroacetic acid is 20: 1;
the preparation method of the B2 comprises the following steps:
(1) preparation of M-5
Dissolving syringic acid in dichloromethane to obtain a dichloromethane solution of syringic acid, sequentially adding potassium hydroxide, potassium carbonate, tetrabutylammonium bromide and water, slowly dropwise adding a dichloromethane solution of bromoborneol under stirring, completing dropwise addition within 30 minutes, and reacting at room temperature for 24 hours to obtain M-5;
the molar ratio of the syringic acid to the potassium hydroxide to the potassium carbonate to the tetrabutylammonium bromide to the bromoborneol is 10:18:10:1: 10;
the mass volume ratio of the tetrabutylammonium bromide to the water is 1g:30 mL;
in the dichloromethane solution of the syringic acid, the mass-volume ratio of the syringic acid to the dichloromethane is 1g:5 mL;
in the dichloromethane solution of the bromoborneol, the mass volume ratio of the bromoborneol to the dichloromethane is 1g: 1.54 mL;
(2) preparation of M-6
Dissolving M-5 in DCM at room temperature, sequentially adding M-3, 4-dimethylaminopyridine p-toluenesulfonate and N, N' -diisopropylcarbodiimide, and reacting at room temperature for 5 h to obtain M-6;
the molar ratio of the M-5, the M-3, the 4-dimethylaminopyridine p-toluenesulfonate to the N, N' -diisopropylcarbodiimide is 1:1.5:2: 2;
the mass-to-volume ratio of the M-5 to the DCM is 1g:18.2 mL;
(3) preparation B2
Dissolving M-6 in dichloromethane, dripping trifluoroacetic acid at 0 ℃, stirring for 5 min, heating to room temperature, and reacting for 8 h to obtain B2;
the mass-volume ratio of the M-6 to the dichloromethane is 1 mg: 0.05 mL; the volume ratio of the dichloromethane to the trifluoroacetic acid is 20: 1;
the structural formulas of M-1, M-2, M-3, M-4, M-5 and M-6 are as follows:
Figure 368248DEST_PATH_IMAGE002
。
2. the use of the leonurine borneol derivative according to claim 1 in the preparation of medicaments for preventing and treating nervous system diseases or cardiovascular and cerebrovascular diseases.
CN202111139180.8A 2021-09-28 2021-09-28 Leonurine borneol derivative, preparation method and application thereof Active CN113603570B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111139180.8A CN113603570B (en) 2021-09-28 2021-09-28 Leonurine borneol derivative, preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111139180.8A CN113603570B (en) 2021-09-28 2021-09-28 Leonurine borneol derivative, preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN113603570A CN113603570A (en) 2021-11-05
CN113603570B true CN113603570B (en) 2022-02-11

Family

ID=78343231

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111139180.8A Active CN113603570B (en) 2021-09-28 2021-09-28 Leonurine borneol derivative, preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN113603570B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115448826B (en) * 2022-09-19 2023-12-08 无锡济煜山禾药业股份有限公司 Separation and identification of natural borneol metabolites

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1410413A (en) * 2002-10-18 2003-04-16 中山大学 Naprosyn precusor, its synthesis method and application
JP2009007258A (en) * 2007-06-26 2009-01-15 Kowa Pharmaceutical Co Ltd 3-anilino-2-cycloalkenone derivative having inhibitory action on production of pai-1
CN102260198A (en) * 2010-05-28 2011-11-30 复旦大学 Leonurine preparation method
RU2448083C2 (en) * 2010-07-16 2012-04-20 Учреждение Российской академии наук Институт химии Коми научного центра Уральского отделения РАН Method of producing isobornyl phenol esters
CN103086926A (en) * 2011-10-27 2013-05-08 复旦大学 Preparation method for leonurine and derivatives thereof
CN103242162A (en) * 2013-05-22 2013-08-14 华东理工大学 Borneol ester derivative of carboxylic acid nonsteraidal anti-inflammatory medicaments as well as preparation method and application of borneol ester derivative
WO2015053797A2 (en) * 2012-11-28 2015-04-16 Yansong Lu Novel synthetic aspirin-mimics and innovative antioxidants and their uses
CN108840808A (en) * 2018-06-13 2018-11-20 北京合力众盈医药科技有限责任公司 A kind of leonurine derivative, preparation method and its usage
CN112552211A (en) * 2020-12-30 2021-03-26 青岛海合生物科技有限公司 Leonurine derivative and application thereof in preparation of medicines for preventing or treating ischemic cerebrovascular diseases

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1410413A (en) * 2002-10-18 2003-04-16 中山大学 Naprosyn precusor, its synthesis method and application
JP2009007258A (en) * 2007-06-26 2009-01-15 Kowa Pharmaceutical Co Ltd 3-anilino-2-cycloalkenone derivative having inhibitory action on production of pai-1
CN102260198A (en) * 2010-05-28 2011-11-30 复旦大学 Leonurine preparation method
RU2448083C2 (en) * 2010-07-16 2012-04-20 Учреждение Российской академии наук Институт химии Коми научного центра Уральского отделения РАН Method of producing isobornyl phenol esters
CN103086926A (en) * 2011-10-27 2013-05-08 复旦大学 Preparation method for leonurine and derivatives thereof
WO2015053797A2 (en) * 2012-11-28 2015-04-16 Yansong Lu Novel synthetic aspirin-mimics and innovative antioxidants and their uses
CN103242162A (en) * 2013-05-22 2013-08-14 华东理工大学 Borneol ester derivative of carboxylic acid nonsteraidal anti-inflammatory medicaments as well as preparation method and application of borneol ester derivative
CN108840808A (en) * 2018-06-13 2018-11-20 北京合力众盈医药科技有限责任公司 A kind of leonurine derivative, preparation method and its usage
CN112552211A (en) * 2020-12-30 2021-03-26 青岛海合生物科技有限公司 Leonurine derivative and application thereof in preparation of medicines for preventing or treating ischemic cerebrovascular diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
冰片药理作用及冰片酯的研究进展;吴谕锋等;《药理研究》;20201231;第39卷(第4期);217-224 *
天然冰片的酯类衍生物合成及其在大鼠体内药物代谢动力学研究;吴祈德;《中国博士学位论文全文数据库 (医药卫生科技辑)》;20150515(第5期);E057-30 *

Also Published As

Publication number Publication date
CN113603570A (en) 2021-11-05

Similar Documents

Publication Publication Date Title
EP0261977B1 (en) Catechol derivatives, and preventive and remedial preparations for regressive disorders in the central nervous system
CN103342729B (en) Substituted ramification of pentacycle triterpene of coffee acyl and application thereof
US7641922B2 (en) Preparation and application of transhintotalphenolic acid
CN113603570B (en) Leonurine borneol derivative, preparation method and application thereof
US20180251440A1 (en) Derivative of inula lineariifolia lactone a
CN111606917B (en) Abietane compound with C-ring-fused lactone ring novel skeleton and preparation method and application thereof
CN101805391B (en) Preparation method of sodium tanshinone IIA for injection
CN103183719A (en) Saponin derivative and application thereof
CN113817007B (en) Gentiopicroside derivative and preparation and application thereof
DE60313804T2 (en) New alpha-glucosidase inhibitors and their synthesis from a natural source
CN103980240A (en) New hydroxysafflor yellow pharmaceutical salt
CN111825608A (en) Tetrahydroquinoline and tetrahydroisoquinoline compounds and application thereof
CN106608824B (en) Aromatic acid ester compound and preparation method and application thereof
US7071341B2 (en) α-Glucosidase inhibitors and their synthesis from a natural source
CN104224796A (en) Application of oleanane triterpene ester derivative in preparation for anti-neurodegeneration medicine
US9775856B2 (en) C-glycosylpolyphenol antidiabetic agents, effect on glucose tolerance and interaction with beta-amyloid. therapeutic applications of the synthesized agent(s) and of Genista tenera ethyl acetate extracts containing some of those agents
CN112409443B (en) Proteborl derivative, preparation method thereof and application thereof in preparation of medicines for treating cardiovascular and cerebrovascular diseases
CN114262299B (en) Anti-neuroinflammatory compound, preparation method and medical application thereof
JPH09100295A (en) Novel triterpenoid saponin and therapeutic agent containing the same as active ingredient and having action of extendingneurite
JPH0386822A (en) Nervous cell alternation-repairing agent
KR100516647B1 (en) Hypoglycemic composition
CN110016069B (en) Tanshinone IIA piperazine compound and preparation method and application thereof
CN107652335B (en) Preparation method of acetyl gastrodin derivative and application of acetyl gastrodin derivative in anti-liver cancer activity
CN106466313A (en) The amide derivatives that one class sulfoamido replaces are used for the purposes in the medicine treating Alzheimer in preparation
CN118026980A (en) Dihydrotrimales wheat flavone and its preparation method and use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant